Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 84 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Company has given Newspaper Advertisement on 16th June, 2023 of notice for opportunity of withdrawal for application subscribed by eligible equity shareholders / RE holders. Earum Pharmaceuticals Ltd - 542724 - Reg. 34 (1) Annual Report.
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Revised Annual Report for Financial Year 2021-22 due to discrepancy related to typographical error in the Cashflow Statement and CARO report added in the Audit report. Further this is inform you that we were already submitted Annual Report for the Financial Year 2021-22, for the rectification the discrepancy we are submitting this revised Annual Report. There are no change in Annual Report other than Cashflow Statement and CARO Report. Kindly take this revised Annual Report on your record and oblige us. Thanking You. Earum Pharmaceuticals Ltd - 542724 - Announcement Regarding Opportunity Of Withdrawal For Application Subscribed By Eligible Equity Shareholders / RE Holders
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to bring to the attention of the investors that there is misprint on page no 40 under the heading of Minimum Subscription in letter of offer dated April 19, 2023, the misprinting is in regards to the applicability of Minimum Subscription, which states that the requirement of minimum subscription in the Issue shall be applicable. Further, we wish to state that same is not applicable as we are satisfying both the conditions a. if object of the issue involves financing other than financing of capital expenditure for a project and b. our Promoter Mr. Bhumishth Patel, vide letter dated 24th January, 2023 has given intend to fully subscribe to their portion of rights entitlement not renounce their rights except to the extent of renunciation within the promoter group. Accordingly, in terms of Regulation 86(2) of the SEBI ICDR Regulations, is not applicable to the Issue. Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 84 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Company has given Newspaper Advertisement on 3rd June, 2023 of notice for opportunity of withdrawal for application subscribed by eligible equity shareholders / RE holders. Earum Pharmaceuticals Ltd - 542724 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to the captioned subject, kindly find attached herewith Annual Secretarial Compliance Report issued under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the year ended on 31st March, 2023. Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement of Audited Financial Results for the Quarter and Financial Year ended on 31st March, 2023 Earum Pharmaceuticals Ltd - 542724 - Disclosures Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Half Year Ended On 31St March, 2023
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions of the Company for the half year ended on 31st March, 2023. Earum Pharmaceuticals Ltd - 542724 - Submission Of Audited Financial Results For The Quarter And Year Ended On 31St March, 2023 Along With Auditor'S Report And Declaration
In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Audited Financial Results for the Quarter and Financial Year ended on 31st March, 2023 along with Auditor's Report and Declaration. Earum Pharmaceuticals Ltd - 542724 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 29Th May, 2023
Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e. on 29th May, 2023, at the Registered Office of the Company, which commenced at 4:00 P.M. and concluded at 6:20 P.M. has considered and approved Audited Financial Results for the Quarter and Financial Year ended on 31st March, 2023 along with Auditor's Report and Declaration.